デフォルト表紙
市場調査レポート
商品コード
1531018

成長ホルモン欠乏症の世界市場:産業分析、規模、シェア、成長、動向、予測(2024~2034年)

Growth Hormone Deficiency Market (Treatment Type: Therapeutic Treatment, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts, and Surgery) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日: | 発行: Transparency Market Research | ページ情報: 英文 145 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.25円
成長ホルモン欠乏症の世界市場:産業分析、規模、シェア、成長、動向、予測(2024~2034年)
出版日: 2024年06月18日
発行: Transparency Market Research
ページ情報: 英文 145 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、世界の成長ホルモン欠乏症市場について、2024~2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018~2034年までの世界の成長ホルモン欠乏症市場の収益と予測を提供しています。また、2024~2034年までの世界の成長ホルモン欠乏症市場の複合年間成長率(CAGR %)も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、産業リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、成長ホルモン欠乏症市場を推察しました。

市場スナップショット
2023年の市場規模 43億米ドル
2034年の市場規模 70億米ドル
CAGR 4.4%

当レポートでは、世界の成長ホルモン欠乏症市場の競合情勢について調査しています。世界の成長ホルモン欠乏症市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介されている世界の成長ホルモン欠乏症市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー:世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場分析・予測、2020~2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主要合併・買収
  • COVID-19による産業への影響

第6章 世界市場分析・予測:治療タイプ別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測:治療タイプ別、2020~2034年
    • 治療
    • 遺伝子組換えヒト成長ホルモン
    • ヒト下垂体腺抽出物
    • 手術
  • 市場魅力分析:治療タイプ別

第7章 世界市場分析・予測:適応疾患別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測:適応疾患別、2020~2034年
    • 小児科
    • 特発性低身長症
    • 妊娠低年齢児
    • ターナー症候群
    • 成人
    • その他(プラダーウィリー症候群など)
  • 市場魅力分析:適応疾患別

第8章 世界市場分析・予測:投与経路別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測:投与経路別、2020~2034年
    • 皮下
    • 筋肉内
    • 静脈内
  • 市場魅力分析:投与経路別

第9章 世界市場分析・予測:流通チャネル別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測:流通チャネル別、2020~2034年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場魅力分析:流通チャネル別

第10章 世界市場分析・予測:地域別

  • 主な調査結果
  • 市場金額予測:地域別、2020~2034年
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力分析:地域別

第11章 北米の市場分析と予測

第12章 欧州の市場分析と予測

第13章 アジア太平洋の市場分析と予測

第14章 ラテンアメリカの市場分析と予測

第15章 中東・アフリカの市場分析と予測

第16章 競合情勢

  • 市場企業 - 競合マトリックス(企業階層と規模別)
  • 市場シェア分析:企業別(2023年)
  • 企業プロファイル
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Merck KGaA
    • Eli Lilly and Company
    • Novartis AG
    • F. Hoffmann-La Roche AG
    • Ipsen Pharma
    • Ferring Pharmaceuticals
    • Anhui Anke Biotechnology(Group)Co., Ltd.
    • Zhongshan Sinobioway Hygene Biomedicine Co., Ltd.
    • その他
図表

List of Tables

  • Table 01: Global Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 02: Global Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
  • Table 03: Global Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 04: Global Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 05: Global Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 06: North America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 07: North America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 08: North America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
  • Table 9: North America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 10: North America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 11: Europe Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 12: Europe Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 13: Europe Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
  • Table 14: Europe Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 15: Europe Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 16: Asia Pacific Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Asia Pacific Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 18: Asia Pacific Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
  • Table 19: Asia Pacific Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 20: Asia Pacific Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 21: Latin America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Latin America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 23: Latin America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
  • Table 24: Latin America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 25: Latin America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 26: Middle East & Africa Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 27: Middle East & Africa Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 28: Middle East & Africa Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
  • Table 29: Middle East & Africa Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 30: Middle East & Africa Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global Growth Hormone Deficiency Market Size (US$ Bn), by Region, 2023 and 2034
  • Figure 02: Global Growth Hormone Deficiency Market Revenue (US$ Bn), by Treatment Type, 2023
  • Figure 03: Global Growth Hormone Deficiency Market Value Share, by Treatment Type, 2023
  • Figure 04: Global Growth Hormone Deficiency Market Revenue (US$ Bn), by Disease Indication, 2023
  • Figure 05: Global Growth Hormone Deficiency Market Value Share, by Disease Indication, 2023
  • Figure 06: Global Growth Hormone Deficiency Market Revenue (US$ Bn), by Route of Administration, 2023
  • Figure 07: Global Growth Hormone Deficiency Market Value Share, by Route of Administration, 2023
  • Figure 08: Global Growth Hormone Deficiency Market Revenue (US$ Bn), by Distribution Channel, 2023
  • Figure 09: Global Growth Hormone Deficiency Market Value Share, by Distribution Channel, 2023
  • Figure 10: Global Growth Hormone Deficiency Market Value Share, by Region, 2023
  • Figure 11: Global Growth Hormone Deficiency Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 12: Global Growth Hormone Deficiency Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 13: Global Growth Hormone Deficiency Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 14: Global Growth Hormone Deficiency Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 15: Global Growth Hormone Deficiency Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 16: Global Growth Hormone Deficiency Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 17: Global Growth Hormone Deficiency Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 18: Global Growth Hormone Deficiency Market Revenue (US$ Bn), by Distribution Channel, 2023
  • Figure 19: Global Growth Hormone Deficiency Market Value Share, by Distribution Channel, 2023
  • Figure 20: Global Growth Hormone Deficiency Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 21: Global Growth Hormone Deficiency Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 22: North America Growth Hormone Deficiency Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 23: North America Growth Hormone Deficiency Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 24: North America Growth Hormone Deficiency Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 25: North America Growth Hormone Deficiency Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 26: North America Growth Hormone Deficiency Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 27: North America Growth Hormone Deficiency Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 28: North America Growth Hormone Deficiency Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 29: North America Growth Hormone Deficiency Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 30: North America Growth Hormone Deficiency Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 31: North America Growth Hormone Deficiency Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 32: North America Growth Hormone Deficiency Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 33: Europe Growth Hormone Deficiency Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 34: Europe Growth Hormone Deficiency Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 35: Europe Growth Hormone Deficiency Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 36: Europe Growth Hormone Deficiency Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 37: Europe Growth Hormone Deficiency Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 38: Europe Growth Hormone Deficiency Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 39: Europe Growth Hormone Deficiency Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 40: Europe Growth Hormone Deficiency Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 41: Europe Growth Hormone Deficiency Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 42: Europe Growth Hormone Deficiency Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 43: Europe Growth Hormone Deficiency Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 44: Asia Pacific Growth Hormone Deficiency Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 45: Asia Pacific Growth Hormone Deficiency Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 46: Asia Pacific Growth Hormone Deficiency Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 47: Asia Pacific Growth Hormone Deficiency Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 48: Asia Pacific Growth Hormone Deficiency Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 49: Asia Pacific Growth Hormone Deficiency Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 50: Asia Pacific Growth Hormone Deficiency Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 51: Asia Pacific Growth Hormone Deficiency Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 52: Asia Pacific Growth Hormone Deficiency Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 53: Asia Pacific Growth Hormone Deficiency Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 54: Asia Pacific Growth Hormone Deficiency Market Attractiveness Analysis, by Distribution Channel, 2023-2034
  • Figure 55: Latin America Growth Hormone Deficiency Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 56: Latin America Growth Hormone Deficiency Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 57: Latin America Growth Hormone Deficiency Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 58: Latin America Growth Hormone Deficiency Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 59: Latin America Growth Hormone Deficiency Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 60: Latin America Growth Hormone Deficiency Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 61: Latin America Growth Hormone Deficiency Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 62: Latin America Growth Hormone Deficiency Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 63: Latin America Growth Hormone Deficiency Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 64: Latin America Growth Hormone Deficiency Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 65: Latin America Growth Hormone Deficiency Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 66: Middle East & Africa Growth Hormone Deficiency Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 67: Middle East & Africa Growth Hormone Deficiency Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 68: Middle East & Africa Growth Hormone Deficiency Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 69: Middle East & Africa Growth Hormone Deficiency Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 70: Middle East & Africa Growth Hormone Deficiency Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 71: Middle East & Africa Growth Hormone Deficiency Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 72: Middle East & Africa Growth Hormone Deficiency Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 73: Middle East & Africa Growth Hormone Deficiency Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 74: Middle East & Africa Growth Hormone Deficiency Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 75: Middle East & Africa Growth Hormone Deficiency Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 76: Middle East & Africa Growth Hormone Deficiency Market Attractiveness Analysis, by Distribution Channel, 2024-2034
目次
Product Code: TMRGL86221

Growth Hormone Deficiency Market - Scope of Report

TMR's report on the global growth hormone deficiency market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global growth hormone deficiency market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global growth hormone deficiency market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the growth hormone deficiency market.

Market Snapshot
Market Value in 2023US$ 4.3 Bn
Market Value in 2034US$ 7 Bn
CAGR4.4%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global growth hormone deficiency market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global growth hormone deficiency market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global growth hormone deficiency market.

The report delves into the competitive landscape of the global growth hormone deficiency market. Key players operating in the global growth hormone deficiency market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global growth hormone deficiency market profiled in this report.

Key Questions Answered in Global growth hormone deficiency Market Report:

  • What is the sales/revenue generated by growth hormone deficiency across all regions during the forecast period?
  • What are the opportunities in the global growth hormone deficiency market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Growth Hormone Deficiency Market - Research Objectives and Research Approach

The comprehensive report on the global growth hormone deficiency market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global growth hormone deficiency market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global growth hormone deficiency market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Growth Hormone Deficiency Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Growth Hormone Deficiency Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Growth Hormone Deficiency Market Analysis and Forecast, by Treatment Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 6.3.1. Therapeutic Treatment
      • 6.3.1.1. Norditropin
      • 6.3.1.2. Genotropin
      • 6.3.1.3. Humatrope
      • 6.3.1.4. Saizen
      • 6.3.1.5. Others (Omnitrope, etc.)
    • 6.3.2. Recombinant Human Growth Hormone
    • 6.3.3. Human Pituitary Gland Extracts
    • 6.3.4. Surgery
  • 6.4. Market Attractiveness, by Treatment Type

7. Global Growth Hormone Deficiency Market Analysis and Forecast, by Disease Indication

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Indication, 2020-2034
    • 7.3.1. Pediatric Growth Hormone Deficiency
    • 7.3.2. Idiopathic Short Stature
    • 7.3.3. Small for Gestational Age
    • 7.3.4. Turner Syndrome
    • 7.3.5. Adult Growth Hormone Deficiency
    • 7.3.6. Others (Prader-Willi Syndrome, etc.)
    • 7.3.7. 7.4 Market Attractiveness, by Disease Indication

8. Global Growth Hormone Deficiency Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2020-2034
    • 8.3.1. Subcutaneous
    • 8.3.2. Intramuscular
    • 8.3.3. Intravenous
  • 8.4. Market Attractiveness, by Route of Administration

9. Global Growth Hormone Deficiency Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness, by Distribution Channel

10. Global Growth Hormone Deficiency Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2020-2034
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Growth Hormone Deficiency Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Treatment Type, 2020-2034
    • 11.2.1. Therapeutic Treatment
      • 11.2.1.1. Norditropin
      • 11.2.1.2. Genotropin
      • 11.2.1.3. Humatrope
      • 11.2.1.4. Saizen
      • 11.2.1.5. Others (Omnitrope, etc.)
    • 11.2.2. Recombinant Human Growth Hormone
    • 11.2.3. Human Pituitary Gland Extracts
    • 11.2.4. Surgery
  • 11.3. Market Attractiveness, by Treatment Type
  • 11.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 11.4.1. Pediatric Growth Hormone Deficiency
    • 11.4.2. Idiopathic Short Stature
    • 11.4.3. Small for Gestational Age
    • 11.4.4. Turner Syndrome
    • 11.4.5. Adult Growth Hormone Deficiency
    • 11.4.6. Others (Prader-Willi Syndrome, etc.)
  • 11.5. Market Attractiveness, by Disease Indication
  • 11.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 11.6.1. Subcutaneous
    • 11.6.2. Intramuscular
    • 11.6.3. Intravenous
  • 11.7. Market Attractiveness, by Route of Administration
  • 11.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.8.1. Hospital Pharmacies
    • 11.8.2. Retail Pharmacies
    • 11.8.3. Online Pharmacies
  • 11.9. Market Attractiveness, by Distribution Channel
  • 11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Treatment Type
    • 11.11.2. By Disease Indication
    • 11.11.3. By Route of Administration
    • 11.11.4. By Distribution Channel
    • 11.11.5. By Country

12. Europe Growth Hormone Deficiency Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Treatment Type, 2020-2034
    • 12.2.1. Therapeutic Treatment
      • 12.2.1.1. Norditropin
      • 12.2.1.2. Genotropin
      • 12.2.1.3. Humatrope
      • 12.2.1.4. Saizen
      • 12.2.1.5. Others (Omnitrope, etc.)
    • 12.2.2. Recombinant Human Growth Hormone
    • 12.2.3. Human Pituitary Gland Extracts
    • 12.2.4. Surgery
  • 12.3. Market Attractiveness, by Treatment Type
  • 12.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 12.4.1. Pediatric Growth Hormone Deficiency
    • 12.4.2. Idiopathic Short Stature
    • 12.4.3. Small for Gestational Age
    • 12.4.4. Turner Syndrome
    • 12.4.5. Adult Growth Hormone Deficiency
    • 12.4.6. Others (Prader-Willi Syndrome, etc.)
  • 12.5. Market Attractiveness, by Disease Indication
  • 12.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 12.6.1. Subcutaneous
    • 12.6.2. Intramuscular
    • 12.6.3. Intravenous
  • 12.7. Market Attractiveness, by Route of Administration
  • 12.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.8.1. Hospital Pharmacies
    • 12.8.2. Retail Pharmacies
    • 12.8.3. Online Pharmacies
  • 12.9. Market Attractiveness, by Distribution Channel
  • 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Treatment Type
    • 12.11.2. By Disease Indication
    • 12.11.3. By Route of Administration
    • 12.11.4. By Distribution Channel
    • 12.11.5. By Country/Sub-region

13. Asia Pacific Growth Hormone Deficiency Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Treatment Type, 2020-2034
    • 13.2.1. Therapeutic Treatment
      • 13.2.1.1. Norditropin
      • 13.2.1.2. Genotropin
      • 13.2.1.3. Humatrope
      • 13.2.1.4. Saizen
      • 13.2.1.5. Others (Omnitrope, etc.)
    • 13.2.2. Recombinant Human Growth Hormone
    • 13.2.3. Human Pituitary Gland Extracts
    • 13.2.4. Surgery
  • 13.3. Market Attractiveness, by Treatment Type
  • 13.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 13.4.1. Pediatric Growth Hormone Deficiency
    • 13.4.2. Idiopathic Short Stature
    • 13.4.3. Small for Gestational Age
    • 13.4.4. Turner Syndrome
    • 13.4.5. Adult Growth Hormone Deficiency
    • 13.4.6. Others (Prader-Willi Syndrome, etc.)
  • 13.5. Market Attractiveness, by Disease Indication
  • 13.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 13.6.1. Subcutaneous
    • 13.6.2. Intramuscular
    • 13.6.3. Intravenous
  • 13.7. Market Attractiveness, by Route of Administration
  • 13.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.8.1. Hospital Pharmacies
    • 13.8.2. Retail Pharmacies
    • 13.8.3. Online Pharmacies
  • 13.9. Market Attractiveness, by Distribution Channel
  • 13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Treatment Type
    • 13.11.2. By Disease Indication
    • 13.11.3. By Route of Administration
    • 13.11.4. By Distribution Channel
    • 13.11.5. By Country/Sub-region

14. Latin America Growth Hormone Deficiency Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Treatment Type, 2020-2034
    • 14.2.1. Therapeutic Treatment
      • 14.2.1.1. Norditropin
      • 14.2.1.2. Genotropin
      • 14.2.1.3. Humatrope
      • 14.2.1.4. Saizen
      • 14.2.1.5. Others (Omnitrope, etc.)
    • 14.2.2. Recombinant Human Growth Hormone
    • 14.2.3. Human Pituitary Gland Extracts
    • 14.2.4. Surgery
  • 14.3. Market Attractiveness, by Treatment Type
  • 14.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 14.4.1. Pediatric Growth Hormone Deficiency
    • 14.4.2. Idiopathic Short Stature
    • 14.4.3. Small for Gestational Age
    • 14.4.4. Turner Syndrome
    • 14.4.5. Adult Growth Hormone Deficiency
    • 14.4.6. Others (Prader-Willi Syndrome, etc.)
  • 14.5. Market Attractiveness, by Disease Indication
  • 14.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 14.6.1. Subcutaneous
    • 14.6.2. Intramuscular
    • 14.6.3. Intravenous
  • 14.7. Market Attractiveness, by Route of Administration
  • 14.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.8.1. Hospital Pharmacies
    • 14.8.2. Retail Pharmacies
    • 14.8.3. Online Pharmacies
  • 14.9. Market Attractiveness, by Distribution Channel
  • 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Treatment Type
    • 14.11.2. By Disease Indication
    • 14.11.3. By Route of Administration
    • 14.11.4. By Distribution Channel
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa Growth Hormone Deficiency Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Treatment Type, 2020-2034
    • 15.2.1. Therapeutic Treatment
      • 15.2.1.1. Norditropin
      • 15.2.1.2. Genotropin
      • 15.2.1.3. Humatrope
      • 15.2.1.4. Saizen
      • 15.2.1.5. Others (Omnitrope, etc.)
    • 15.2.2. Recombinant Human Growth Hormone
    • 15.2.3. Human Pituitary Gland Extracts
    • 15.2.4. Surgery
  • 15.3. Market Attractiveness, by Treatment Type
  • 15.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 15.4.1. Pediatric Growth Hormone Deficiency
    • 15.4.2. Idiopathic Short Stature
    • 15.4.3. Small for Gestational Age
    • 15.4.4. Turner Syndrome
    • 15.4.5. Adult Growth Hormone Deficiency
    • 15.4.6. Others (Prader-Willi Syndrome, etc.)
  • 15.5. Market Attractiveness, by Disease Indication
  • 15.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 15.6.1. Subcutaneous
    • 15.6.2. Intramuscular
    • 15.6.3. Intravenous
  • 15.7. Market Attractiveness, by Route of Administration
  • 15.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 15.8.1. Hospital Pharmacies
    • 15.8.2. Retail Pharmacies
    • 15.8.3. Online Pharmacies
  • 15.9. Market Attractiveness, by Distribution Channel
  • 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Treatment Type
    • 15.11.2. By Disease Indication
    • 15.11.3. By Route of Administration
    • 15.11.4. By Distribution Channel
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. Novo Nordisk A/S
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Pfizer Inc.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Merck KGaA
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Eli Lilly and Company
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Novartis AG
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. F. Hoffmann-La Roche AG
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Ipsen Pharma
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Ferring Pharmaceuticals
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Anhui Anke Biotechnology (Group) Co., Ltd.
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Zhongshan Sinobioway Hygene Biomedicine Co., Ltd.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. Others
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview